Skip to main content
  • English
  • Español
Oryzon
  • Company
    • Overview
    • Strategy
    • Team
  • Epigenetics
    • Epigenetics
    • LSD1
  • Programs
    • Pipeline
    • Iadademstat
    • Vafidemstat
    • Collaborations
    • Publications
  • Patients
    • Clinical Trials
  • Investors
    • Share Information
      • Share Performance
      • Shares and Capital Structure
      • Dividends
      • Share Issues
      • Takeover Bids
      • Shareholdings
    • Financial Information
      • Financial Results and Accounts
      • Public Periodic Information
      • Average supplier payment period
    • CNMV Filings
    • Analyst Coverage
    • Corporate Governance
      • General Shareholders Meeting
      • Board of Directors
      • Board Committees
      • Shareholder Agreements
      • Annual Corporate Governance Reports
      • Annual Director Remuneration Reports
    • Corporate Social Responsibility
  • News & Events
    • Press releases
    • Events
  • Contact
    • Contact
    • Email Alerts
    • Join us

Breadcrumb

  1. Home
5 January 2016

Oryzon to Attend the 34th Annual J.P. Morgan Healthcare Conference in San Francisco

23-24 June 2025

Discovery and Development Europe 2025

Congress Center

Basel

Switzerland

16-19 June 2025

BIO International Convention 2025

Boston Convention & Exhibition Center, Boston

MA

United States

27-29 May 2025

Foro MedCap 2025

Madrid Stock Exchange Palace

Madrid

Spain

27 May 2025

ORYZON to provide corporate progress updates at several events in May-June

27 June 2025

Ordinary General Shareholders’ Meeting 2025

Madrid

Spain

12 May 2025

ORYZON reports financial results and corporate update for quarter ended March 31, 2025

8 May 2025

ORYZON awarded 13.26 million € through the first Important Project of Common European Interest (IPCEI) in the health sector (Med4Cure project)

24 April 2025

ORYZON Raises €30 Million in Capital Increase

21 April 2025

ORYZON continues to strengthen its patent portfolio for vafidemstat

Pagination

  • First page « First
  • Previous page ‹ Previous
  • Current page 1
  • Page 2
  • Page 3
  • Page 4
  • Page 5
  • Page 6
  • Page 7
  • Page 8
  • Page 9
  • Next page Next ›
  • Last page Last »
Subscribe to
Logo Oryzon
  • Company
    • Overview
    • Strategy
    • Team
  • Epigenetics
    • Epigenetics
    • LSD1
  • Programs
    • Pipeline
    • Iadademstat
    • Vafidemstat
    • Collaborations
    • Publications
  • Patients
    • Clinical Trials
  • Investors
    • Share Information
    • Financial Information
    • CNMV Filings
    • Analyst Coverage
    • Corporate Governance
    • Corporate Social Responsibility
  • News & Events
    • Press releases
    • Events
  • Contact
    • Contact
    • Email Alerts
    • Join us
  • © Oryzon Genomics, S.A. - All Rights Reserved

    • Legal
    • Privacy Policy
    • Cookie Policy
    • Ethics Channel